Burning Rock Biotech (BNR) Cost of Revenue: 2020-2025
Historic Cost of Revenue for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to $5.9 million.
- Burning Rock Biotech's Cost of Revenue fell 19.35% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year decrease of 20.08%. This contributed to the annual value of $26.2 million for FY2024, which is 25.04% down from last year.
- As of Q3 2025, Burning Rock Biotech's Cost of Revenue stood at $5.9 million, which was up 9.33% from $5.4 million recorded in Q2 2025.
- In the past 5 years, Burning Rock Biotech's Cost of Revenue ranged from a high of $16.5 million in Q4 2021 and a low of $5.4 million during Q2 2025.
- In the last 3 years, Burning Rock Biotech's Cost of Revenue had a median value of $6.7 million in 2024 and averaged $7.1 million.
- As far as peak fluctuations go, Burning Rock Biotech's Cost of Revenue soared by 77.03% in 2021, and later tumbled by 42.96% in 2023.
- Burning Rock Biotech's Cost of Revenue (MRQ) stood at $16.5 million in 2021, then fell by 17.75% to $13.6 million in 2022, then tumbled by 42.96% to $7.8 million in 2023, then fell by 27.73% to $5.6 million in 2024, then grew by 5.94% to $5.9 million in 2025.
- Its last three reported values are $5.9 million in Q3 2025, $5.4 million for Q2 2025, and $5.6 million during Q1 2025.